Compare · ACHV vs OCDX
ACHV vs OCDX
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Ortho Clinical Diagnostics Holdings plc (OCDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and OCDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- OCDX is the larger of the two at $4.08B, about 4.9x ACHV ($840.7M).
- ACHV has hit the wire 6 times in the past 4 weeks while OCDX has been quiet.
- ACHV has more recent analyst coverage (10 ratings vs 8 for OCDX).
- Company
- Achieve Life Sciences Inc.
- Ortho Clinical Diagnostics Holdings plc
- Price
- -
- -
- Market cap
- $840.7M
- $4.08B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 10
- 8
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Latest ACHV
- Director Stewart Richard Alistair sold $175,177 worth of shares (20,626 units at $8.49), decreasing direct ownership by 9% to 208,249 units (SEC Form 4)
- Morgan Stanley initiated coverage on Achieve Life Sciences with a new price target
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
- Achieve Life Sciences Announced Granting of New Hire Inducement Awards
- SEC Form 4 filed by Director Sellig Thomas
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Royston Aaron
Latest OCDX
- SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc
- SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Busky Joseph M
- SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Palaniappan Chockalingam
- SEC Form 4: Yates Robert Clifton returned 323,880 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Christopher M returned 367,360 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Dilsaver Evelyn S returned 5,200 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Mac Mahon Thomas P returned 141,853 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Labrum Ronald K returned 109,985 units of Ordinary Shares to the company, closing all direct ownership in the company